世界のAPI中間体市場2023年-2032年:種類別(API中間体、化学中間体)、用途別(鎮痛薬、抗感染症薬、抗糖尿病薬、心臓血管薬、抗がん薬、その他)、エンドユーザー別(バイオテクノロジー企業&製薬会社、CMO、その他)

【英語タイトル】API Intermediate Market By Type (Bulk Drug Intermediates, Chemical Intermediates), By Application (Analgesics, Anti-Infective Drugs, Antidiabetic Drugs, Cardiovascular Drugs, Anticancer Drugs, Others), By End User (Biotech and Pharmaceutical Companies, CMO, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Researchが出版した調査資料(ALD23SEP153)・商品コード:ALD23SEP153
・発行会社(調査会社):Allied Market Research
・発行日:2023年6月
・ページ数:390
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:生命科学
◆販売価格オプション(消費税別)
Online Only(1名閲覧、印刷不可)USD3,570 ⇒換算¥542,640見積依頼/購入/質問フォーム
Single User(1名閲覧)USD5,730 ⇒換算¥870,960見積依頼/購入/質問フォーム
Enterprise User(閲覧人数無制限)USD9,600 ⇒換算¥1,459,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

API中間体市場の2022年の市場規模は1,394億2,109万ドルで、2032年には2,849億5,344万ドルに達すると推定され、2023年から2032年までの年平均成長率は7.4%です。医薬品有効成分(API)は、医薬品の製造に使用される物質または物質の組み合わせです。医薬品有効成分の製剤化に使用される原料はAPI中間体として知られています。API中間体は、原薬の製造過程で生成される物質です。API中間体には、化学中間体とAPI中間体の2種類があります。API中間体とは、医薬品の製造過程で生成される化学物質や化合物を指します。一方、化学中間体とは、医薬品、農薬、染料、ポリマー、その他の工業製品を含む様々な化学物質の合成や製造の過程で生成される化合物や物質のことです。

API中間体市場の成長は、慢性疾患の有病率の上昇と老人人口の増加が原動力となっています。API中間体は、腫瘍学、循環器学、中枢神経系(CNS)および神経学、整形外科学、呼吸器学、消化器学、腎臓学、眼科学、内分泌学などの疾患の治療に使用される高品質の医薬品に応用されています。原薬と中間体は、より革新的な製品を導入することで、より持続可能な医療システムを構築できる可能性があります。そのため、心疾患などの慢性疾患に罹患する人口の増加は、API中間体の需要を煽り、市場の成長を後押しすると予想されます。例えば、英国心臓財団(British Heart Foundation)によると、英国では2022年に約1,139,140人が心臓・循環器系疾患に罹患しています。同じ情報源によると、2022年に英国で心臓および循環器系疾患に罹患した人口は、男性が約650,681人、女性が約488,320人でした。さらに、米国心臓協会によると、2020年には2億4410万人が虚血性心疾患(IHD)に罹患していると推定されています。同資料によると、IHDは女性より男性の方が多く、それぞれ1億4,100万人と1億310万人でした。

また、米国癌協会によると、2022年に米国で新たに発見される癌の症例は約1,918,030件です。さらに、世界がん研究基金インターナショナル(WCRFI)の報告によると、2020年には世界で約1,810万人のがん患者が新たに発見されるとのことです。さらに、肺疾患や消化器疾患を患う人口の増加は、API中間体の需要を増加させ、市場の成長を促進すると予想されています。慢性閉塞性肺疾患に対する世界的な取り組み(GOLD)は、2022年に2億人が慢性閉塞性肺疾患(COPD)に罹患しており、そのうち約320万人が毎年死亡しており、世界的に死因の第3位になっていると報告しています。また、同出典によると、喘息は最も一般的な非感染性疾患のひとつであり、2022年には世界で2億6,200万人が罹患するとされています。
API中間体を製造する企業の存在感の高さが、市場の成長を後押しすると予想されます。例えば、Shubham Specialty Products社、Akums Drugs & Pharmaceuticals Ltd.社、Vasoya Industrial Pvt. Lmt.社、Corey Organics社、Icon Pharma Chem社、SLN Pharmachem社などは、API中間体を製造する主要な市場参入企業です。

しかし、バイオ医薬品の取得に関連する高コストは、世界のAPI中間体市場の成長を妨げる主な要因です。また、API中間体の製造に必要な設備投資額が高いことも、市場の成長を抑制すると予想されます。
その一方で、インド、中国、日本など、各国の政府による医療インフラ整備のためのイニシアチブの高まりや、API中間体製造装置の開発に対する支出の増加は、予測期間中の市場拡大に有益な機会を提供すると予想されます。

世界のAPI中間体市場は、タイプ、用途、エンドユーザー、地域に区分されます。タイプ別では、API中間体市場と化学中間体市場に分けられます。用途別では、市場は鎮痛薬、抗感染薬、抗糖尿病薬、心血管治療薬、抗がん薬、その他に区分されます。エンドユーザー別では、バイオ・製薬企業、CMO、研究所に区分されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。
世界のAPI中間体市場で事業を展開している主要企業には、Anyang General Chemical Co., Ltd.、Sandoo Pharmaceuticals、Evonik Industries AG、Shree Ganesh Remedies Limited、Pfizer、Cambrex Corporation、Zeal & Innovation in Medicine、cation pharma、Hikal Ltd.、Espeeなどがあります。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までのAPI中間体市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、API中間体市場の実勢機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
API中間体市場のセグメンテーションを詳細に分析し、市場機会を特定します。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
API中間体の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
タイプ別
API中間体
化学中間体

用途別
鎮痛薬
抗感染症薬
抗糖尿病薬
循環器系薬剤
抗がん剤
その他

エンドユーザー別
バイオテクノロジーおよび製薬企業
CMO
その他

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Anyang General Chemical Co., Ltd.
○ Cambrex Corporation
○ Cation Pharma
○ Espee
○ Evonik Industries AG.
○ Hikal Ltd
○ Pfizer Inc.
○ Sandoo Pharmaceuticals
○ Shree Ganesh Remedies Limited
○ Zeal & Innovation in Medicine

第1章:イントロダクション
第2章:エグゼクティブサマリー
第3章:市場概要
第4章:API中間体市場、タイプ別
第5章:API中間体市場、用途別
第6章:API中間体市場、エンドユーザー別
第7章:API中間体市場、地域別
第8章:競争状況
第9章:企業情報

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic disease
3.4.1.2. High presence of market players
3.4.1.3. Surge in number of geriatric populations

3.4.2. Restraints
3.4.2.1. Stringent government rules

3.4.3. Opportunities
3.4.3.1. Rapid growth of biopharmaceutical industry
3.4.3.2. Increase in adoptions of key strategies by market players.

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: API INTERMEDIATE MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Bulk Drug Intermediates
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chemical Intermediates
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: API INTERMEDIATE MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Analgesics
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Anti-Infective Drugs
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Antidiabetic Drugs
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Cardiovascular Drugs
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Anticancer Drugs
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Others
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
CHAPTER 6: API INTERMEDIATE MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Biotech and Pharmaceutical Companies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. CMO
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: API INTERMEDIATE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Type
7.2.5.1.3. Market size and forecast, by Application
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Type
7.2.5.2.3. Market size and forecast, by Application
7.2.5.2.4. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Type
7.2.5.3.3. Market size and forecast, by Application
7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Type
7.3.5.1.3. Market size and forecast, by Application
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Type
7.3.5.2.3. Market size and forecast, by Application
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Type
7.3.5.3.3. Market size and forecast, by Application
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Type
7.3.5.4.3. Market size and forecast, by Application
7.3.5.4.4. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Type
7.3.5.5.3. Market size and forecast, by Application
7.3.5.5.4. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Type
7.3.5.6.3. Market size and forecast, by Application
7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Type
7.4.5.1.3. Market size and forecast, by Application
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Type
7.4.5.2.3. Market size and forecast, by Application
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Type
7.4.5.3.3. Market size and forecast, by Application
7.4.5.3.4. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Type
7.4.5.4.3. Market size and forecast, by Application
7.4.5.4.4. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Type
7.4.5.5.3. Market size and forecast, by Application
7.4.5.5.4. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Type
7.4.5.6.3. Market size and forecast, by Application
7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Type
7.5.5.1.3. Market size and forecast, by Application
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Type
7.5.5.2.3. Market size and forecast, by Application
7.5.5.2.4. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Type
7.5.5.3.3. Market size and forecast, by Application
7.5.5.3.4. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Type
7.5.5.4.3. Market size and forecast, by Application
7.5.5.4.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Anyang General Chemical Co., Ltd.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.2. Sandoo Pharmaceuticals
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.3. Evonik Industries AG.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Shree Ganesh Remedies Limited
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Cambrex Corporation
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Key strategic moves and developments
9.6. Zeal & Innovation in Medicine
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Cation Pharma
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Espee
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Hikal Ltd
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Pfizer Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. API INTERMEDIATE MARKET FOR BULK DRUG INTERMEDIATES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. API INTERMEDIATE MARKET FOR CHEMICAL INTERMEDIATES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 05. API INTERMEDIATE MARKET FOR ANALGESICS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. API INTERMEDIATE MARKET FOR ANTI-INFECTIVE DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. API INTERMEDIATE MARKET FOR ANTIDIABETIC DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. API INTERMEDIATE MARKET FOR CARDIOVASCULAR DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. API INTERMEDIATE MARKET FOR ANTICANCER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. API INTERMEDIATE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 12. API INTERMEDIATE MARKET FOR BIOTECH AND PHARMACEUTICAL COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. API INTERMEDIATE MARKET FOR CMO, BY REGION, 2022-2032 ($MILLION)
TABLE 14. API INTERMEDIATE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. API INTERMEDIATE MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. U.S. API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. CANADA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. CANADA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. MEXICO API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 28. MEXICO API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. EUROPE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. EUROPE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. EUROPE API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. GERMANY API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. FRANCE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. FRANCE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. UK API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 40. UK API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 41. UK API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. ITALY API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. ITALY API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. SPAIN API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. SPAIN API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. JAPAN API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 57. JAPAN API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. CHINA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. CHINA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. INDIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 62. INDIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. INDIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 73. LAMEA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 74. LAMEA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 75. LAMEA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 76. LAMEA API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 79. BRAZIL API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. ANYANG GENERAL CHEMICAL CO., LTD.: KEY EXECUTIVES
TABLE 90. ANYANG GENERAL CHEMICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 91. ANYANG GENERAL CHEMICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 92. ANYANG GENERAL CHEMICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 93. SANDOO PHARMACEUTICALS: KEY EXECUTIVES
TABLE 94. SANDOO PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 95. SANDOO PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 96. SANDOO PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 97. EVONIK INDUSTRIES AG.: KEY EXECUTIVES
TABLE 98. EVONIK INDUSTRIES AG.: COMPANY SNAPSHOT
TABLE 99. EVONIK INDUSTRIES AG.: PRODUCT SEGMENTS
TABLE 100. EVONIK INDUSTRIES AG.: PRODUCT PORTFOLIO
TABLE 101. SHREE GANESH REMEDIES LIMITED: KEY EXECUTIVES
TABLE 102. SHREE GANESH REMEDIES LIMITED: COMPANY SNAPSHOT
TABLE 103. SHREE GANESH REMEDIES LIMITED: PRODUCT SEGMENTS
TABLE 104. SHREE GANESH REMEDIES LIMITED: SERVICE SEGMENTS
TABLE 105. SHREE GANESH REMEDIES LIMITED: PRODUCT PORTFOLIO
TABLE 106. CAMBREX CORPORATION: KEY EXECUTIVES
TABLE 107. CAMBREX CORPORATION: COMPANY SNAPSHOT
TABLE 108. CAMBREX CORPORATION: PRODUCT SEGMENTS
TABLE 109. CAMBREX CORPORATION: SERVICE SEGMENTS
TABLE 110. CAMBREX CORPORATION: PRODUCT PORTFOLIO
TABLE 111. CAMBREX CORPORATION: KEY STRATERGIES
TABLE 112. ZEAL & INNOVATION IN MEDICINE: KEY EXECUTIVES
TABLE 113. ZEAL & INNOVATION IN MEDICINE: COMPANY SNAPSHOT
TABLE 114. ZEAL & INNOVATION IN MEDICINE: PRODUCT SEGMENTS
TABLE 115. ZEAL & INNOVATION IN MEDICINE: PRODUCT PORTFOLIO
TABLE 116. CATION PHARMA: KEY EXECUTIVES
TABLE 117. CATION PHARMA: COMPANY SNAPSHOT
TABLE 118. CATION PHARMA: PRODUCT SEGMENTS
TABLE 119. CATION PHARMA: PRODUCT PORTFOLIO
TABLE 120. ESPEE: KEY EXECUTIVES
TABLE 121. ESPEE: COMPANY SNAPSHOT
TABLE 122. ESPEE: PRODUCT SEGMENTS
TABLE 123. ESPEE: PRODUCT PORTFOLIO
TABLE 124. HIKAL LTD: KEY EXECUTIVES
TABLE 125. HIKAL LTD: COMPANY SNAPSHOT
TABLE 126. HIKAL LTD: PRODUCT SEGMENTS
TABLE 127. HIKAL LTD: PRODUCT PORTFOLIO
TABLE 128. PFIZER INC.: KEY EXECUTIVES
TABLE 129. PFIZER INC.: COMPANY SNAPSHOT
TABLE 130. PFIZER INC.: PRODUCT SEGMENTS
TABLE 131. PFIZER INC.: PRODUCT PORTFOLIO

★調査レポート[世界のAPI中間体市場2023年-2032年:種類別(API中間体、化学中間体)、用途別(鎮痛薬、抗感染症薬、抗糖尿病薬、心臓血管薬、抗がん薬、その他)、エンドユーザー別(バイオテクノロジー企業&製薬会社、CMO、その他)] (コード:ALD23SEP153)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のAPI中間体市場2023年-2032年:種類別(API中間体、化学中間体)、用途別(鎮痛薬、抗感染症薬、抗糖尿病薬、心臓血管薬、抗がん薬、その他)、エンドユーザー別(バイオテクノロジー企業&製薬会社、CMO、その他)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆